Dechra Pharmaceuticals described trading in the first quarter of its financial year as “strong” in an update on Thursday.
The FTSE 250 veterinary medicine company, which was holding its annual general meeting, said that was particularly true in the United States as it continued to outperform the sector, and benefit from strong growth in the companion animal market.
“Although trading is currently encouraging, it remains too early in the year to extrapolate this performance across the full year,” the board said in its short statement.
Dechra said it would announce its interim results for the six months ended 31 December on 21 February.
